phone icon (917) 310-3371 Book a Lynkuet evaluation
Nao Medical

Lynkuet evaluation for menopause symptoms in NYC

Lynkuet is a nonhormonal bedtime prescription for moderate to severe vasomotor symptoms due to menopause. Evaluation includes pregnancy exclusion when relevant, baseline liver tests, medication interactions, seizure history, and the risk of sleepiness or daytime impairment.

Nao Medical clinic visit
Nao Medical clinic interior
Nao Medical patient care
Lynkuet evaluation Treatment begins only after the clinician confirms that the symptom target, pregnancy status, liver results, medicines, and follow-up plan fit the current label.

Quick answer

Lynkuet is a nonhormonal bedtime prescription for moderate to severe vasomotor symptoms due to menopause. Evaluation includes pregnancy exclusion when relevant, baseline liver tests, medication interactions, seizure history, and the risk of sleepiness or daytime impairment.

Eligibility and care boundaries

The visit begins with the clinical question and the records that can change the next step.

Symptom fit

The treatment target is moderate to severe hot flashes or night sweats due to menopause, not every menopause symptom.

Pregnancy boundary

Lynkuet is contraindicated in pregnancy, and pregnancy must be excluded for patients with reproductive potential.

Liver and seizure review

Baseline hepatic tests, a three-month follow-up test, liver history, and seizure history are part of the safety review.

Interaction and impairment review

Grapefruit, CYP3A4 inhibitors or inducers, and medicines that add sedation can change the plan.

How care works

Confirm the treatment target

The clinician reviews symptom severity, timing, bleeding, sleep, and conditions that can resemble or complicate menopause.

Complete safety screening

The visit covers pregnancy possibility, liver testing, seizure history, kidney or liver impairment, and all medicines and supplements.

Plan access and dosing

If appropriate, the clinician discusses the current bedtime regimen, interaction-based dose changes, coverage, and pharmacy access.

Reassess after treatment starts

Follow-up covers response, daytime impairment, liver-test completion, new medicines, and any warning symptoms.

Lynkuet has distinct nervous-system, pregnancy, and liver boundaries

Lynkuet is not hormone therapy. It is an NK1 and NK3 receptor antagonist for moderate to severe vasomotor symptoms due to menopause.

The current label warns about somnolence, fatigue, dizziness, vertigo, and other nervous-system effects. A patient who feels impaired should not drive or do hazardous work until the effects resolve.

Lynkuet does not replace evaluation of unexpected bleeding, pelvic pain, vaginal symptoms, a breast concern, thyroid disease, anemia, pregnancy, or another cause of symptoms.

Get urgent help for serious symptoms and stop Lynkuet for possible liver injury

Stop Lynkuet and contact the prescribing clinician immediately for symptoms that suggest liver injury. Call 911 for a seizure lasting five minutes or longer, repeated seizures without recovery, severe allergic symptoms, chest pain, stroke symptoms, or another emergency. Do not drive if sleepiness or dizziness makes it unsafe.

Insurance and access

As a newer medicine, Lynkuet coverage can vary by formulary, pharmacy, prior authorization, and interaction-based dose. Benefits review begins after clinical eligibility is established and does not guarantee approval or cost.

Clinics available for Lynkuet evaluation and coordination

These clinic cards are evaluation access points. Confirm an eligible clinic before arrival. They do not promise medication inventory, prescribing, laboratory completion, or same-day access at every site.

Nao Medical Mineola clinic

Long Island

Mineola

135 Mineola Blvd, Mineola, NY 11501

Evaluation and coordination only. Confirm an eligible clinic for the exact medicine, test, injection, insertion, removal, or infusion before treatment.

Book a Lynkuet evaluation Call (917) 310-3371

Related care

Choose the related care that matches the question you want the clinician to address.

Veozah evaluation

Compare another nonhormonal option with a different liver-monitoring and interaction profile.

Women's health

Coordinate preventive and gynecologic care when the symptom pattern is broader.

Current official medical sources

Medical information was checked against the official sources below on August 1, 2026. The treating clinician confirms the current label and guidance for each patient.

National Library of Medicine DailyMed

Lynkuet (elinzanetant) current U.S. prescribing information

Indication, bedtime dosing, pregnancy exclusion, hepatic testing, daytime impairment, seizure warning, interactions, and renal and hepatic limits.

Read the official source

U.S. Food and Drug Administration

Drug Trials Snapshot: Lynkuet

FDA approval status, approved menopause-related use, administration summary, and pivotal-trial context.

Read the official source

Frequently asked questions

Lynkuet is FDA approved for moderate to severe vasomotor symptoms, such as hot flashes and night sweats, due to menopause.
No. Lynkuet is a nonhormonal NK1 and NK3 receptor antagonist.
The labeled regimen is taken at bedtime, and the medicine can cause sleepiness, fatigue, dizziness, or other nervous-system effects. Follow the prescriber's instructions.
The label calls for pregnancy exclusion when relevant and baseline hepatic laboratory testing. Hepatic transaminases are checked again three months after treatment starts.
Pregnancy is a contraindication. End-stage renal disease and moderate to severe hepatic impairment are not recommended uses. Seizure history, liver results, and interacting medicines also need clinician review.
The label says to avoid grapefruit and strong CYP3A4 inhibitors. Moderate inhibitors require a lower labeled dose, and moderate or strong inducers should be avoided. A clinician or pharmacist should check the full list.
It can cause daytime impairment. Do not drive or do hazardous work if sleepiness, dizziness, vertigo, fatigue, or similar effects occur until they resolve.
Coverage and cost vary by plan, formulary, prior authorization, pharmacy, and eligibility. An evaluation can begin the access review but cannot guarantee approval.
Nao Medical

Start with the right evaluation

Treatment begins only after the clinician confirms that the symptom target, pregnancy status, liver results, medicines, and follow-up plan fit the current label.

Medical content checked against the sources above on August 1, 2026.

Health information notice

General information only. This page is not medical advice and does not replace diagnosis, treatment, or guidance from a licensed clinician.

Content was updated August 1, 2026 from the sources cited on this page. Medical guidance, prescribing information, medication availability, and insurance rules can change. A licensed clinician must confirm current information and determine each patient's eligibility, testing, treatment, administration setting, and follow-up. Call 911 for a medical emergency. Contact Nao Medical with a question or correction.